TAG:
lab executive
Quest Ready to Move on Unilab, Announces Its 2002 Earnings
By Robert Michel | From the Volume X No. 2 – February 10, 2003 Issue
PERSISTENCE IS ABOUT TO PAY OFF for Quest Diagnostics Incorporated. After ten months of effort, it expects to finalize its acquisition of Unilab Corporation within weeks. But the Unilab acquisition soon to close looks different than the acquisition that was original…
New Trends in 2003 Affect Clinical Lab Services
By Robert Michel | From the Volume X No. 1 – January 20, 2003 Issue
CEO SUMMARY: Here’s our current list of macro trends that affect clinical laboratories, updated from the last list in January 2000. One bold prediction is that Medicare, as we know it, is on the verge of a major meltdown. Employers and consumers are also new forces to be reckoned with b…
Laboratories Sit Squarely Between New Genetics and Today’s Medicine
By Robert Michel | From the Volume IX No. 18 – December 30, 2002 Issue
“Clinical laboratories and pathology groups are at the leading edge of the genetic revolution.” —Rick J. Carlson. CEO SUMMARY: Healthcare futurist Rick J. Carlson believes that knowledge of the human genome will trigger revolutionary…
It’s a Feud in North Carolina! LabCorp Versus Spectrum
By Robert Michel | From the Volume IX No. 17 – December 9, 2002 Issue
OVER IN NORTH CAROLINA, one of those good, old-fashioned southern feuds is under way. Like the fabled feud between the Hatfields and the McCoys of years past, Spectrum Laboratory Network and Laboratory Corporation are in a full-fledged shoot-out over market share of…
Will “Free Testing” Ploy Financially Affect Labs?
By Robert Michel | From the Volume IX No. 12 – August 26, 2002 Issue
CEO SUMMARY: It’s a marketing scheme which public lab companies have quietly used for years. Now there is evidence that the use of “Waiver of Charges to Managed Care Patients” (free testing) seems to be on the increase, raising new questions about how and why competitive practices a…
Dade Behring Primed To Become Public Firm
By Robert Michel | From the Volume IX No. 11 – August 5, 2002 Issue
CEO SUMMARY: Dade Behring is executing an ambitious plan to restructure its finances and become a public company. To reduce its debt burden, Dade’s three owners are giving up their stock. Banks and bondholders will swap a portion of their debt for shares of stock in Dade. Once the finan…
Boost for Consumer Choice in Healthcare
By R. Lewis Dark | From the Volume IX No. 10 – July 15, 2002 Issue
OVERLOOKED BY MOST LAB EXECUTIVES AND PATHOLOGISTS was a ruling made last month by the Internal Revenue Service (IRS). It was a significant ruling, but neither the media nor many people in the United States understood its significance. As a result, this ruling got little news coverage. But for the l…
“July 15, 2002 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume IX No. 10 – July 15, 2002 Issue
In many states, pathologists were hit by substantial increases in the cost of malpractice. In some states, like Pennsylvania, the market for medical malpractice insurance has deteriorated substantially. In the case of AmeriPath, Inc., the nation’s largest operator of hospital-based…
Specialty Labs Struggles To Maintain Operations
By Robert Michel | From the Volume IX No. 9 – June 24, 2002 Issue
CEO SUMMARY: In April, Specialty Laboratories, Inc. disclosed that state and federal regulators had placed sanctions on the esoteric testing company, including revocation of its CLIA-88 license, subject to legal appeal. One main source of concern is the fact that, over the past 10 weeks, …
Big Fight is Brewing Over Lab Test Reimbursement
By R. Lewis Dark | From the Volume IX No. 8 – June 3, 2002 Issue
BY NOW, MOST LAB EXECUTIVES AND PATHOLOGISTS AGREE that Medicare Part B fees and reimbursement guidelines for lab testing have just about become de facto national standards. That’s because private payers increasingly use Medicare as the basis for building their own pricing and reimbursement guideli…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized